Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Ribosomal protein L36a pseudogene 23 (RPL36AP23)** is a processed pseudogene of the RPL36A gene, which encodes a component of the 60S ribosomal subunit involved in protein synthesis[4][3]. Pseudogenes like RPL36AP23 do not produce functional proteins and generally lack known biological functions, drug interactions, or disease associations[4]. As a pseudogene, it is not considered a therapeutic target, and there is no evidence to suggest clinical or pharmacological relevance[3][4]. **Notes:** - This entry corresponds to a pseudogene, not a functional protein or receptor; pseudogenes are typically not considered valid drug targets because they do not encode active biomolecules[4]. - There is no evidence linking RPL36AP23 with disease, therapeutic intervention, or biomarkers; these associations are known for some functional ribosomal proteins, not pseudogenes like RPL36AP23[4]. - If a functional or disease-associated ribosomal protein is intended (e.g., RPL36A, RPL36AL), please clarify the query, as those have distinct molecular and clinical properties[4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L36a pseudogene 23 (RPL36AP23).